Volume 12, Number 1—January 2006
Research
Economics of Neuraminidase Inhibitor Stockpiling for Pandemic Influenza, Singapore
Table 3
Strategy option | Stockpile cost (1 cycle, million $) | Lives saved compared with no action | Cost per life saved compared with no action ($100,000) | Benefit compared with no action (million $) |
---|---|---|---|---|
No action | Not applicable | Deaths: 1,105 (525, 1,775) | Not applicable | Cost: 1,430 (730, 2,193) |
Only Rx‡ | 79 | 423 (183, 756) | 38 (dominates§, 395) | 379 (89, 734) |
6 wk¶ | 631 | 492 (216, 870) | 2,246 (811, 4,676) | –487 (–925, 48) |
12 wk¶ | 1183 | 684 (286, 1,264) | 3,193 (1,008, 6,788) | –1,188 (–1,934, –265) |
18 wk¶ | 1735 | 850 (377, 1,442) | 3,668 (1,358, 7,363) | –1,920 (–2,941, –783) |
24 wk¶ | 2,287 | 903 (425, 1,509) | 4,516 (1,828, 9,022) | –2,811 (–4,070, –1,384) |
*Mean values are shown with 5th and 95th percentiles in parentheses.
†All healthcare costs are in 2004 Singapore dollars.
‡Only Rx refers to treatment only, without prophylaxis.
§Treatment-only dominates no action because treatment-only saves lives and is less costly overall.
¶No. of weeks of prophylaxis for the respective risk and age groups.
1"Dominate" is a term used in cost-effectiveness analyses and refers to a strategy that is both more efficacious and less costly than another strategy.
Page created: February 16, 2012
Page updated: February 16, 2012
Page reviewed: February 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.